期刊文献+

无症状脑梗死患者血清S100B蛋白和NSE测定的临床意义 被引量:2

暂未订购
导出
摘要 无症状脑梗死常因无临床症状或临床症状较轻微使患者和医生忽视对本病的诊治而给患者带来伤害。NSE和S100B蛋白是反映脑损伤的神经化学标志物,有研究发现急性脑梗死患者血清中NSE和S100B蛋白的含量明显上升^[1,2]。由于脑梗死后血液中NSE和S100B蛋白的含量上升,美国学者建议临床脑梗死试验时,
出处 《实验与检验医学》 CAS 2008年第5期572-572,共1页 Experimental and Laboratory Medicine
  • 相关文献

参考文献5

  • 1[1]Lee JG,Oh SH,Na SJ,et al.The effect of initial serum neuron-specific enolase level on clinical outcome in acute carotid artery territory infarction[J].J Yonsei Med,2002,43(3):357~362.
  • 2[2]Tiainen M,Roine R,Pettila V,et al.Serum neuron-specific enolase and S100B protein in cardiac arrest patients treated with hypothermia[J].Stroke,2003,34(12):2881~2886.
  • 3[3]Stroke therapy academic industry roundtable Ⅱ(STAIR-Ⅱ),Recommendations for clinical trial evaluation of acute stroke therapies[J].Stroke,2001,32(7):1598~1606.
  • 4[4]Wiesman M,Missler U,Cottmamn D,et al.Plasma S100B protein concentration in healthy adult is age and sex independent[J].Clin them,1998,44:1055~1057.
  • 5[5]Haffideld RH,Mckcman RM.CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model[J].Brain Res,1992,572(2):249~252.

同被引文献11

  • 1Gruson D, Ko G. Galelectins testing:new promises for the diagnosis and risk stratification of chronic diseases?[J].Clin Biochem,2012,45 (10-11):719-726.
  • 2Marenholz I,Heizmann CW.S100A16,a ubiquitously expressed EF- hand protein which is up-regulated in tumor [J]. Biochem Biophys Res Commun,2009,313(2):237-244.
  • 3Kapural M,Krizanac-Bengez L,Barnett G, et al.Serum S-100beta as a possible marker of blood-brain barrier disruption [J].Brain Res, 2002,940(1-2): 102-104.
  • 4de Boer RA ,Verweij N,van Veldhuisen DJ,et al. A genonae-wide association study of circulating galectin-3 [J]. PLoS One,2012,7 (10):e47385.
  • 5Anzai T, Post-infarction inflammation and left ventrieular remodel- ing:a double-edged sword[J].Circ J, 2013,77:(3)580-587.
  • 6Falcone C,Luclbello S, Mazzuchelli I,et al. Galectin-3 plasma lev- els and coronary artery diseases:a new possible biomarker of acute coronary syndrome [J]. Int J Immunopathol Pharmacol,2011,24(4): 905 -913.
  • 7Lok DA,Van Der Meer P, Pieta W , et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study [J]. Clin Res Cardiol, 2010,99(5):323-328.
  • 8Lainscak M,Coletta AP, Sherwi N, et al.Clinieal trials update from the Heart Faliure Society of America Meeting 2009: FAST, LM- PROVE-HF, COACH galectin-3 substudy , HF-ACTION nuclear substudy ,DAD-HF, and MARVEL-I [J]. Eur J Heart Fail,2010, 12(2): 193 - 196.
  • 9Grandin EW, Jarolim P, Murphy SA , et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 [J]. Clin Chem,2012,58(1): 267-273.
  • 10中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,43(2):146-153. 被引量:3408

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部